Corebridge Financial Inc. Sells 11,070 Shares of Standard BioTools Inc. (NASDAQ:LAB)

Corebridge Financial Inc. trimmed its stake in Standard BioTools Inc. (NASDAQ:LAB) by 7.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 146,654 shares of the company’s stock after selling 11,070 shares during the quarter. Corebridge Financial Inc.’s holdings in Standard BioTools were worth $257,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its stake in Standard BioTools by 188.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company’s stock valued at $4,719,000 after buying an additional 1,597,728 shares during the period. State Street Corp raised its holdings in Standard BioTools by 26.7% in the 3rd quarter. State Street Corp now owns 5,495,136 shares of the company’s stock valued at $10,606,000 after acquiring an additional 1,157,984 shares during the period. Royce & Associates LP boosted its holdings in shares of Standard BioTools by 136.8% during the fourth quarter. Royce & Associates LP now owns 1,455,503 shares of the company’s stock worth $2,547,000 after acquiring an additional 840,951 shares during the period. Barclays PLC lifted its holdings in Standard BioTools by 13.2% during the 3rd quarter. Barclays PLC now owns 3,228,360 shares of the company’s stock worth $6,231,000 after purchasing an additional 377,195 shares during the last quarter. Finally, GM Advisory Group LLC acquired a new position in Standard BioTools in the 4th quarter valued at $350,000. Institutional investors and hedge funds own 53.74% of the company’s stock.

Standard BioTools Trading Up 4.5 %

LAB stock opened at $1.15 on Friday. The stock has a market capitalization of $435.83 million, a P/E ratio of -1.62 and a beta of 1.54. The firm has a 50-day moving average price of $1.20 and a 200-day moving average price of $1.61. Standard BioTools Inc. has a 12 month low of $0.97 and a 12 month high of $2.94.

Analyst Upgrades and Downgrades

Separately, KeyCorp lowered shares of Standard BioTools from an “overweight” rating to a “sector weight” rating in a research report on Thursday, February 27th.

Insider Buying and Selling

In other news, Director Casdin Partners Master Fund, L acquired 4,820,959 shares of Standard BioTools stock in a transaction dated Friday, February 28th. The shares were bought at an average cost of $1.06 per share, with a total value of $5,110,216.54. Following the purchase, the director now owns 58,846,780 shares in the company, valued at $62,377,586.80. This trade represents a 8.92 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 53.10% of the stock is owned by corporate insiders.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.